Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 15, 2004

Primary Completion Date

May 19, 2006

Study Completion Date

May 19, 2006

Conditions
Melanoma
Interventions
DRUG

SB-485232

Trial Locations (20)

2145

GSK Investigational Site, Westmead

2298

GSK Investigational Site, Waratah

3002

GSK Investigational Site, East Melbourne

4101

GSK Investigational Site, South Brisbane

4102

GSK Investigational Site, Woolloongabba

4814

GSK Investigational Site, Douglas

6009

GSK Investigational Site, Nedlands

7000

GSK Investigational Site, Hobart

10016

GSK Investigational Site, New York

21093

GSK Investigational Site, Lutherville-Timonium

32209

GSK Investigational Site, Jacksonville

33140

GSK Investigational Site, Miami Beach

46202

GSK Investigational Site, Indianapolis

60637

GSK Investigational Site, Chicago

90089

GSK Investigational Site, Los Angeles

94115

GSK Investigational Site, San Francisco

90404-2104

GSK Investigational Site, Santa Monica

06520

GSK Investigational Site, New Haven

43614-5809

GSK Investigational Site, Toledo

15213-2584

GSK Investigational Site, Pittsburgh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY